Quick Ebola vax development could assist with future outbreaks; GSK touts 'major' Synflorix label expansion;

> The rapid development of Merck's ($MRK) Ebola vaccine--which this week was reported to protect 100% of patients in a Phase III trial--could provide a model for addressing future outbreaks. More

> The Committee for Medicinal Products for Human Use (CHMP) granted GlaxoSmithKline's ($GSK) Synflorix a label expansion to include effectiveness data for protection against invasive pneumococcal disease and pneumonia and acute otitis media caused by the pneumococcus bacterium. Release

> BiondVax ($BVXV) reported that its universal flu vaccine candidate, administered in a Phase II trial 3 years ago, provided patients with increased immunogenicity against influenza strains that didn't exist at the time of the study. Release

And Finally... A 15-year-old developed a vapor-compression refrigeration system requiring minimal power to transport vaccines. More

Suggested Articles

Dr. Anthony Fauci will oversee most of the ongoing COVID-19 vaccine trials in the U.S., save for Pfizer's, ProPublica reports.

COVID vaccine and drug trial pauses show that the system is working as intended to verify safety and efficacy, the FDA commissioner told Bloomberg. 

COVID-19 vaccine manufacturing partner Emergent BioSolutions should be protected from financial fallout should J&J's product fail, analysts said.